Vertex Pharmaceuticals (VRTX) now up 57% premarket after reporting positive test results last...

|About: Vertex Pharmaceuticals I... (VRTX)|By:, SA News Editor

Vertex Pharmaceuticals (VRTX) now up 57% premarket after reporting positive test results last night. Previously bullish Deutsche raises its price target to $100 from $75, thinking the company could earn $10/share in 2015 and putting the stock's fair value as high as $150. Goldman's on the case, upgrading to Hold from Sell and raising its price target to $86 from $38.